

Beta-lactomics: A New Term Coined in “OMICS”

Asad U Khan*

Medical Microbiology and Molecular Biology laboratory Interdisciplinary Biotechnology Unit, A.M.U., Aligarh, India

In English language OMICS informally refers to a field of study in biology ending in *-omics*, such as genomics, proteomics, metabolomics, transcriptomics etc. The related suffix *-ome* is used to address the objects of study of these fields such as the genome, proteome, metabolome and transcriptome respectively. The Omics aims at the complete characterization and quantification of pools of biological molecules and their structural and functional insight of an organism. The idea of beta-lactomics came after the worldwide spread of different groups of beta-lactamases and their variants among different strains of bacteria [1,2]. Beta-lactamases are enzymes coded by specific gene and produced in bacteria to hydrolyze antibiotics and hence cause drug resistance against antibiotics a major health problem. A total of about hundreds of variants of each groups of beta-lactamases have been identified and documented in form of manuscripts and databases in the public domain [3-5]. The structural and function diversity of these enzymes are remarkable as evident from the fact that a single mutation may changed its activity towards antibiotic hydrolysis. Some of the structures of these beta-lactamases have been explored using X-ray crystallography and other biophysical techniques but still there are many left in the pool which has not yet been solved for their structural and functional understanding. It is important to understand the structure of these enzymes to map the newly designed lead molecules as future drug candidate [6]. Designing drug is an emerging area as it has become a need of an hour since almost all antibiotics are getting ineffective after the discovery of “Superbug” and spread of NDM-1 enzyme [7,8]. Moreover, natural products are also screened against bacterial infections caused by multiple drug resistant strains. We have proposed several novel approaches to inhibit the action of these enzymes in bacteria [9,10]. The study is in progress on these aspects of beta-lactamases besides their epidemiology and surveillance studies in order to control hospital infection. Hence, a new name as beta-lactomics may be given to this field of beta-lactamases and their emerging variants in bacteria causing multiple drug resistance.

Hence, I am proposing a new term (Beta-lactomics) for this field. It has become a need in the current scenario to understand the whole lot of proteins of this kind circulating in the environment and hospital

setting. The control measures of infection can be attained by designing new empirical treatment based on the information gathered through this field. Moreover, databases of these enzymes and proteins are also required to provide functional and structural information for the researchers working in this area.

References

1. Khan AU, Nordmann P (2012) Spread of carbapenemase NDM-1 producers: the situation in India and what may be proposed. *Scand J Infect Dis* 44: 531-535.
2. Khan AU, Nordmann P (2012) NDM-1-producing *Enterobacter cloacae* and *Klebsiella pneumoniae* from diabetic foot ulcers in India. *J Med Microbiol* 61: 454-456.
3. Danishuddin M, Khan AU (2011) Molecular modeling and docking analysis of beta-lactamases with inhibitors: a comparative study. *In Silico Biol* 11: 273-280.
4. Ali SZ, Ali SM, Khan AU (2014) Prevalence of Inc11-γ and IncFIA-FIB type plasmids in extended-spectrum β-lactamase-producing *Klebsiella pneumoniae* strains isolated from the NICU of a North Indian hospital. *Microbiology* 160: 1153-1161.
5. Danishuddin M, Hassan Baig M, Kaushal L, Khan AU (2013) BLAD: a comprehensive database of widely circulated beta-lactamases. *Bioinformatics* 29: 2515-2516.
6. Nichols DA, Jaishankar P, Larson W, Smith E, Liu G, et al. (2012) Structure-based design of potent and ligand-efficient inhibitors of CTX-M classA β-lactamase. *J Med Chem* 55: 2163-2172.
7. Faheem M, Rehman MT, Danishuddin M, Khan AU (2013) Biochemical characterization of CTX-M-15 from *Enterobacter cloacae* and designing a novel non-β-lactam-β-lactamase inhibitor. *PLoS One* 8: e56926.
8. Danishuddin M, Khan A, Faheem M, Kalaiarasan P, Hassan Baig M, et al. (2014) Structure-based screening of inhibitors against KPC-2: designing potential drug candidates against multidrug-resistant bacteria. *J Biomol Struct Dyn* 32: 741-750.
9. Islam B, Khan SN, Naeem A, Sharma V, Khan AU (2009) Novel effect of plant lectins on the inhibition of *Streptococcus mutans* biofilm formation on saliva-coated surface. *J Appl Microbiol* 106: 1682-1689.
10. Khan R, Islam B, Akram M, Shakil S, Ahmad A, et al. (2009) Antimicrobial activity of five herbal extracts against multi drug resistant (MDR) strains of bacteria and fungus of clinical origin. *Molecules* 14: 586-597.

*Corresponding author: Asad U Khan, Medical Microbiology and Molecular Biology laboratory Interdisciplinary Biotechnology Unit, A.M.U., Aligarh-202002, India; E-mail: asad.k@rediffmail.com

Received October 25, 2014; Accepted October 28, 2014; Published October 29, 2014

Citation: Khan AU (2014) Beta-lactomics: A New Term Coined in “OMICS”. *J Proteomics Bioinform* 7: e27. doi:[10.4172/jpb.10000e27](http://dx.doi.org/10.4172/jpb.10000e27)

Copyright: © 2014 Khan AU. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.